Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab

Journal of Digestive Diseases

Volumn 12, Issue 5, 2011, Pages 379-383

  Verma, Himanshu Dev ^a   Scherl, Ellen Janice ^b   Jacob, Vinita Elizabeth ^b   Bosworth, Brian Paul ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Anti nuclear antibody; Inflammatory bowel disease; Systemic lupus erythematosus; Tumor necrosis factor inhibitor

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; CERTOLIZUMAB PEGOL; INFLIXIMAB;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; FEMALE; HUMAN; LUPUS LIKE SYNDROME; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRALGIA; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFLAMMATORY BOWEL DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80053415444     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2011.00522.x     Document Type: Article

References (25)

1. Targan SR, Hanauer SB, van Deventer SJ etal. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
2. Hanauer SB, Feagan BG, Lichtenstein GR etal. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
3. Hanauer SB, Sandborn WJ, Rutgeerts P etal. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
4. Sandborn WJ, Rutgeerts P, Enns R etal. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38.
5. Colombel JF, Sandborn WJ, Rutgeerts P etal. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
6. Sandborn WJ, Feagan BG, Stoinov S etal. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week placebo-controlled phase III study. (PRECiSE1). Gastroenterology 2006; 130: A-107.
7. Sandborn WJ, Colombel JF, Panes J, Scholmerich J, McColm JA, Schreiber S. Higher remission and maintenance of response rates with subcutaneous monthly certolizumab pegol in patients with recent-onset Crohn's disease: data from PRECiSE 2. Am J Gastroenterol 2006; 101: S454-455.
8. Colombel J, Schreiber S, Hanauer SB etal. Long-term tolerability of subcutaneous certolizumab pegol in active Crohn's disease: results from PRECISE 3 and 4. Gastroenterology 2007; 132: A503.
9. Rutgeerts P, Sandborn W, Feagan B etal. Infliximab for induction and maintenenace therapy for ulcerative colitis. N Engl J Med 2005; 353 (23): 2462.
10. D'Haens G, Baert F, van Assche G etal. Early combined Immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-7.
11. Hommes D, Baert F, van Assche G etal. The ideal management of Crohn's disease: top down versus step up strategies, a randomized controlled trial. Gastroenterology 2006; 130: A-108.
12. Nesbitt A, Fossati G, Bergin M etal. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13: 1323-32.
13. Costa M, Said N, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor agents. Semin Arthritis Rheum 2008; 37: 381-7.
14. Ramos-Casals M, Brito-Zeron P, Munoz S etal. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007; 86: 242-51.
15. De Bandt M, Sibilia J, Le Loet X etal. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Club Rhumatismes et Inflammation. Arthritis Res Ther 2005; 7: R545-51.
16. Bacquet-Deschryver H, Jouen F, Quillard M etal. Impact of three anti-TNF-alpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. J Clin Immunol 2008; 28: 445-55.
17. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo controlled trials. Arthritis Rheum 2000; 43: 2383-90.
18. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121: 1145-57.
19. Van den Brande JMH, Braat H, van den Brink GR etal. Infliximab but not etanercept induced apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-85.
20. D'Auria F, Rovere-Qeurini P, Giazzon M etal. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med 2004; 255: 409-18.
21. Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001; 167: 6821-6.
22. Ferraccioli G, Mecchia F, Di Poi E, Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002; 61: 358-61.
23. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Leonard MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995; 377: 348-51.
24. Fossati G, Nesbitt A. In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870). Am J Gastroenterol 2005; 100: S299.
25. Fossati G, Nesbitt AM. Effect of the anti-TNF agents, adalimumab, etanercept, infliximab, and certolizumab PEGOL (CDP870) on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes. [Abstract] Am J Gastroenterol 2005; 100: S298-S299.